A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
NCT03144674
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
110
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma
Interventions
DRUG:
Parsaclisib
Sponsor
Incyte Corporation